Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

The blues and the jitters are very common among people battling chronic pain, a new evidence review says. About 40% of adults ...

Tiago Costa discusses why ultrasound neuromodulation has significant potential to transform the treatment of depression ...

Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

J&J is discontinuing the Phase 3 test of its drug, aticaprant, in major depressive disorder “due to insufficient efficacy in the target patient population,” the company said after Thursday’s ...

Even though clinical depression in older people is common, that doesn't mean it's normal. Research shows that late-life depression affects about 6 million Americans ages 65 and older, but only 10% get ...

In a statement released Thursday afternoon, J&J said it will stop developing the drug, called aticaprant, as an add-on ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...